Rus Eng
Main / Company's news / Dementia: not a reason for refreshing

Dementia: not a reason for refreshing

22 September 2014

World Alzheimer’s Day is observed on 21 September every year. This trend is aimed at drawing public’s attention towards the problem of such socially significant disease as acquired dementia, which affects a vast number of able-bodied elderly people in different countries. Today dementia can truly be called “the plague of the 21st century”; according to the WHO, currently 35.6 million people are living with dementia across the world. This figure is expected to double by 2030, reaching 65.7 million, and more than triple by 2050, exceeding 115 million people. Average life expectancy with this disease is 8-10 years. According to experts, the total number of people with Alzheimer’s disease in Russia may be approximately of 1.8 million.

Dementia (Latin: Dementia, madness) is acquired mental retardation, persistent reduction of cognitive activity with loss of acquired knowledge and practical experience and the difficulty or impossibility of acquiring new ones. The disease is manifested by problems with memory, impaired judgment, language, orientation, communication, and executive functions. These most common symptoms are more often occur in the elderly. Epidemiological data show that rate of dementia is at least 10% in the age group of 65-75 years and from 15 to 20% in the age group of 80 years and above.

It’s no coincidence that GEROPHARM turned to the issue of dementia. Neurology is one of priorities for the group of companies. GEROPHARM’s portfolio includes original drugs Cortexin (effective neuroprotector) and Cortexin for children (dosage form for children). Levetinol (effective antiepileptic agent) entered the market in 2013. In pursuit of its consistent policy of expanding the portfolio in existing product lines, the company began to produce another drug in this line: Memantinol, a modern medicine for the treatment of moderate to severe Alzheimer’s type dementia. The drug improves cognitive processes and increases daily activity. Memantinol enters the Russian market with the slogan “Dementia: not a reason for refreshing.”

The company is planning to present the drug to the medical community on the 21st of September, a landmark date for the worldwide fight against Alzheimer’s disease.

Today, the awareness about dementia among Russian citizens is unfortunately far from the scale of the problem. Many families which faced the first symptoms of the disease in a loved one (forgetfulness, untidiness, loss of interest in life) attribute them to the natural aging process and only visit a doctor when the disease gets worse. Meanwhile, a timely therapy allows to delay all unpleasant effects which reduce the quality of life of patients and their relatives for several years.

For several years now, GEROPHARM’s active outreach and awareness-raising efforts have supplemented its mainstream activities in the field of development and production of modern pharmaceuticals. The company annually initiates activities and joins global initiatives aimed at raising public awareness about preventive measures of socially significant diseases and assistance in the rehabilitation and socialization of people with neurological diseases. Release of the new neurological drug and dementia awareness rising is another important step to be taken by the company in the direction of improving the quality of life of people.


World Alzheimer’s Day is observed every year since 1994 on the initiative of the Alzheimer Disease International (ADI).

Alois Alzheimer (14 June 1864, Marktbreit, Germany) is a German psychiatrist and neuropathologist, author of numerous articles concerning such issues as alcoholic psychosis, schizophrenia, epilepsy, cerebral syphilis, Huntington’s chorea, arteriosclerotic brain atrophy (1894), presenile psychosis (1907). He received a medical degree in Würzburg and subsequently lived and worked in Frankfurt.

Alzheimer made a significant contribution to the research of nervous system disorders. His research of senile dementia which later became known as Alzheimer’s disease immortalized his name. Relying on the results of his own fundamental research, Alzheimer described the main differences between vascular and neurodegenerative dementias. German psychiatrist Emil Kraepelin, a colleague of Alzheimer, later named a type of senile dementia after Alzheimer.

You are a health care professional?

Go up